Like other products in the series, ColdZyme Eucalyptus creates a protective barrier in the throat that helps reduce the viral load, shorten the duration of a cold, and relieve symptoms. The ColdZyme range previously included menthol and strawberry flavours - with Eucalyptus now introduced as a fresh, cooling alternative.  

"With ColdZyme Eucalyptus, we want to give consumers another choice - without compromising on quality or performance. Many associate eucalyptus with freshness and free breathing, making it a natural addition to our portfolio," says Claus Egstrand, CEO of Enzymatica AB. 

The launch of ColdZyme Eucalyptus will take place in October in Sweden. The product will be available in pharmacies and online.

ColdZyme has been shown in peer-reviewed studies^[1] to reduce viral load by up to 94 percent and shorten the duration of a cold by an average of 40 percent.

About ColdZyme®

ColdZyme® is a CE-marked mouth spray designed to create a protective barrier in the throat. It is supported by clinical studies showing reduced duration and severity of common colds when used as directed. Read more about the latest independent study here: https://coldzyme.enzymatica.com

ColdZyme® is a registered trademark of Enzymatica AB. Always read the label and instructions for use.

References
[1] Davison G et al. 2025  ColdZyme® reduces viral load and upper respiratory tract infection duration and protects airway epithelia from infection with human rhinoviruses. The Journal of Physiology. 2025;603(6):1483-1501. doi:10.1113/JP288136. PubMed: 40019230. https://physoc.onlinelibrary.wiley.com/doi/10.1113/JP288136